Evidence map›Paper›PMID 41909498›Full record

ArticleKidney diseases (Basel, Switzerland)

Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis.

Ping Li, Yu An, Hongguang Zheng, Weiping Lu, Zhaohui Mo, Xudong Xu, Yibing Lu, Chaoqing Wu, Jingyuan Xie, Nanwei Tong and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ping LiNanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Yu AnNational Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
Hongguang ZhengGeneral Hospital of Northern Theater Command, Shenyang, China.
Weiping LuThe Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Nanjing, China.
Zhaohui MoThe Third Xiangya Hospital of Central South University, Changsha, China.
Xudong XuFudan University Minhang Hospital, Shanghai, China.
Yibing LuThe Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chaoqing WuThe People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Jingyuan XieDepartment of Nephrology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nanwei TongWest China Hospital, Sichuan University, Chengdu, China.
Fang LiuWest China Hospital, Sichuan University, Chengdu, China.
Qinkai ChenThe First Affiliated Hospital of Nanchang University, Nanchang, China.
Jingjing TangMedical Affairs China, Pharmaceutical, Bayer Healthcare Co. Ltd., Beijing, China.
Meike BrinkerCardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany.
Luke RobertsCardiology and Nephrology Clinical Development, Bayer PLC, Reading, UK.
Dalong ZhuNanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Zhihong LiuNational Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduced the risk of heart and kidney outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD trials. This subanalysis explored the efficacy and safety of finerenone vs. placebo in Chinese patients. Methods: Patients with CKD (urine albumin-to-creatinine ratio 30-5,000 mg/g, estimated glomerular filtration rate [eGFR] ≥25 mL/min/1.73 m Results: In this Chinese patient subanalysis ( Conclusion: Finerenone demonstrated kidney benefits, favorable trends on CV outcome, and a manageable safety profile in the FIDELITY Chinese subpopulation.

Indexed as

Chinese patientsChronic kidney diseaseFIDELITYFinerenoneType 2 diabetes

Identifiers

PMID41909498
PMCPMC13021231

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.